Origin Agritech's Three New Corn Varieties Pass Preliminary National Review, Advancing Toward Commercialization
Key Highlights
- ➤Three Origin Agritech corn varieties passed preliminary national approval review.
- ➤Aoxiangyu 819 outyielded controls 8.6% in two-year regional trials.
- ➤Aoyu 966 outyielded controls 6.9% in two-year regional trials.
- ➤Aoyu 288 outyielded controls 6.0% in two-year regional trials.
- ➤30-day public notice period runs through November 22, 2026, before final approval steps.
Expert Statements
Weibin Yan, Chief Executive Officer of Origin Agritech
“The preliminary review of these three varieties is an important milestone for Origin's breeding and commercialization pipeline. Their consistent yield performance across regional and production trials demonstrates the strength of our breeding capabilities and provides additional products for our expansion in the Huang-Huai-Hai region.”
Weibin Yan, Chief Executive Officer of Origin Agritech
“As we enter the Strong Growth Stage of our development plan, expanding our variety portfolio remains a key priority. Combined with our growing regional sales network and technology platform, these new varieties strengthen our foundation for sustainable growth and our long-term goal of becoming one of China's leading corn seed companies.”
Aoxiangyu 819, Aoyu 966, and Aoyu 288 delivered yield gains of 6.0% to 8.6% over control varieties in two-year national regional trials; 30-day public notice period runs through November 22, 2026
BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Origin Agritech Limited (NASDAQ: SEED) ("Origin" or the "Company"), a leading Chinese agricultural technology company, today announced that three of its corn varieties, Aoxiangyu 819, Aoyu 966, and Aoyu 288, have passed the preliminary review of the 13th Session of the Fifth National Crop Variety Approval Committee of China. The three varieties are bred for the Huang-Huai-Hai Summer Corn Region, one of China's major corn-producing areas, and each outyielded its designated control variety in both the two-year national regional trials and the 2025 production trials.
Get started
Create a free account to read the full story.